Impact of Melanoma Adjuvant Treatment With Tafinlar + Mekinist (Dabrafenib + Trametinib) on Patients Quality of Life (QoL) and Clinical Outcomes in Portuguese Real World Setting
Latest Information Update: 01 Jun 2023
Price :
$35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 May 2023 Status changed from recruiting to completed.
- 25 Nov 2021 Status changed from not yet recruiting to recruiting.
- 27 Aug 2021 Planned End Date changed from 1 Aug 2022 to 2 Oct 2023.